Automated Author ProfileBaric, Ralph
Baric, Ralph
Current S-Index
Sum of Dataset Indices for all datasets
Average Dataset Index per Dataset
Average Dataset Index per dataset
Total Datasets
Total datasets for this author
Average FAIR Score
Average FAIR Score per dataset
Total Citations
Total citations to the author's datasets
Total Mentions
Total mentions of the author's datasets
S-Index Interpretation
The S-Index (Sharing Index) is a comprehensive metric that represents the cumulative impact of all your datasets. It is calculated as the sum of Dataset Index scores across all your claimed datasets.
What it means:
- A higher S-index indicates greater overall impact of your datasets relative to typical datasets in their fields of research
- The S-Index grows as you add more datasets or as existing datasets gain more citations and mentions
- It provides a single number to track your research data impact over time
Current S-Index: 27.5 (sum of 41 datasets Dataset Index scores)
More information here.
S-Index Over Time
Cumulative Citations Over Time
Cumulative Mentions Over Time
Datasets
To isolate a large panel of Pan-betacoronavirus broadly neutralizing Antibodies and to understand the molecular basis for their broad protection.
Authors
- Baric, Ralph ;
- Martinez, David
To evaluate the molecular composition and binding epitopes of the immunoglobulin G (IgG) antibodies that circulate in blood plasma after SARS-CoV-2 infection.
Authors
- Baric, Ralph ;
- Ippolito, Gregory ;
- James Lavinder, Jason
To discover and characterize broadly neutralizing antibodies that are protective against divergent SARS related viruses.
Authors
- Martinez, David ;
- Baric, Ralph
To evaluate whether vaccine elicited neutralizing antibodies can protect against in vivo challenge with heterologous epidemic and bat coronaviruses.
Authors
- Martinez, David ;
- Baric, Ralph
To demonstrate the effectiveness of Burkholderia oklahomensis agglutinin (BOA) in the inhibition of SARS- CoV-2 viral entry.
Authors
- Baric, Ralph ;
- Martinez, David
To investigate the evidence for therapeutic efficacy of the bispecific antibodies scFv-Fc Ab 2-7/Ab 12 which serves as a foundation for the future development of broadly reactive bispecific antibodies against emerging variants of concern.
Authors
- Alter, Galit ;
- Baric, Ralph
To evaluate the impact of adjuvant formulation on the safety and efficacy of inactivated vaccine during homologous or heterologous coronavirus challenge.
Authors
- Martinez, David ;
- Lakshmanane, Prem ;
- Baric, Ralph
To study viral replicative fitness of SARS-CoV-2 variants of concern in primary human airway cells.
Authors
- Baric, Ralph
To evaluate the immunogenicity of the monovalent versus the trivalent RBD scNP vaccines protection against Sarbecovirus subgenus and Merbecovirus subgenus coronavirus infections in mice.
Authors
- Martinez, David ;
- Baric, Ralph
To evaluate the effect of the D614G substitution on viral replication, pathogenesis, and transmissibility in SARS-CoV-2 infection models.
Authors
- Desilva, Aravinda ;
- Bartelt, Luther ;
- Margolis, David ;
- Baric, Ralph